EDWARD R. AHRENS, M.D.; THOMAS S. KALUZYNSKI, M.D.; VED V. GOSSAIN, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Although human insulin of recombinant DNA and semisynthetic origin has been available for general use for at least a year, the exact indications for its use have not been clearly defined. The clinical potential of human insulin has been outlined by Dr. Skyler (1). A recent review in The Medical Letter (2) has agreed with Dr. Skyler's recommendations that because of human insulin's favorable immunogenicity (less antigenic, less immunogenic), its use may be indicated in patients with immunologic complications of insulin therapy (immunologic insulin resistance, insulin allergy, and lipoatrophy). Additionally, human insulin may be preferable in patients
AHRENS ER, KALUZYNSKI TS, GOSSAIN VV. Total Parenteral Nutrition and Human Insulin. Ann Intern Med. 1984;101:567. doi: 10.7326/0003-4819-101-4-567_1
Download citation file:
Published: Ann Intern Med. 1984;101(4):567.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use